Journal of Immunology Research / 2016 / Article / Tab 1 / Review Article
Effector, Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune Response Table 1 Classification of human CD8+ T cell fates based on surface markers, transcription profiles, and observed phenotype.
CD8+ T cell fate Surface marker profile Transcription profile Phenotype Effector [18 –22 ] (i) KLRG1+ (ii) CD43+ (iii) CD62L− (iv) CD69+ (v) CD95+ (vi) CD137+ (i) T-bet /Eomes (ii) Blimp-1 (iii) Runx3 (iv) Stat4/Stat5 (v) Id2 (i) Direct cytotoxicity against transformed and virus-infected cells (ii) Mediate cytotoxicity through Fas/FasL and granzyme/perforin Central memory [23 –28 ] (i) CCR7+ (ii) CD44+ (iii) CD45RO+ (iv) CD62L+ (v) CD122+ (vi) CD127+ (vii) IL15R+ (i) T-bet /Eomes (ii) Bcl6 (iii) Tcf1 (iv) Stat3 (v) Id3 (vi) WNT-β -catenin (i) Less differentiated (ii) Residing in lymph nodes, spleen, bone marrow, and blood (iii) No immediate effector function (iv) Differentiating into upon antigen rechallenge (v) Self-renewal capacity (vi) IL-7/IL-15 dependence Effector memory [23 –28 ] (i) CCR7− (ii) CD44+ (iii) CD45RO+ (iv) CD62L− (v) CD127+ (vi) KLRG1+ (i) T-bet /Eomes (ii) Blimp-1/Bcl-6 (i) Found in both lymphoid and peripheral tissues (ii) Rapidly release effector molecules (iii) Highly cytotoxic (iv) Intermediate differentiation stage (v) Rapidly differentiate into upon antigen rechallenge Exhausted [29 –33 ] (i) CD45RO+ (ii) CD57+ (iii) CD95+ (iv) PD-1+ (v) CTLA-4+ (vi) Tim-3+ (vii) Lag-3+ (viii) BTLA+ (i) NFAT (ii) T-bet /Eomes (iii) Blimp-1 (iv) BATF (v) FoxP1 (i) Reduced proliferation (ii) Decreased cytokine production (iii) Reduced cytotoxicity (iv) Reduced IFNγ and IL-2 secretion (v) Eventual cell death Anergic/tolerant [34 –41 ] (i) Lag-3+ (ii) PD-1+ (i) NFAT (ii) NF-kB/RelA (iii) Ikaros (iv) Egr1/Egr2 (i) Reduced IL-2 secretion (ii) Reduced proliferation Senescent/regulatory [42 –44 ] (i) KLRG1+ (ii) CD28− (iii) CD57+ (i) FoxP3 (i) Cell-cycle arrest (ii) Immunosuppressive